Opendata, web and dolomites

AB-DiRecT SIGNED

Antibiotic Distribution and Recovery in Tissue

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AB-DiRecT project word cloud

Explore the words cloud of the AB-DiRecT project. It provides you a very rough idea of what is the project "AB-DiRecT" about.

antibiotics    tonsil    positive    data    pathogens    single    ab    vitro    antibacterial    trials    pharyngeal    prostatectomy    healthy    penetration    urogenital    determinants    body    surgery    broad    negative    gsk    healthcare    treat    class    discovery    animal    caused    explore    resistant    tonsillectomy    direct    exposure    active    subjects    infections    gonorrhoea    model    classes    infection    acute    mechanism    treatment    pbpk    threat    understand    poppk    levels    regimens    elective    resistance    prostatitis    dose    infected    models    contemporary    antimicrobials    economic    determined    clinical    action    difference    pkpd    conduct    explored    gepotidacin    requiring    uncomplicated    prostate    antibacterials    urinary    tissue    sites    gram    antimicrobial    coli    burden    isolates    urgent    selective    gonorrhoeae    microdialysis    pk    undergoing    triazaacenaphthylene    tract    health    fluoroquinolones    efficacy    first    provision    plasma    imposes    oral    agents   

Project "AB-DiRecT" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙789˙717 €
 EC max contribution 3˙429˙217 € (90%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-16-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙234˙278.00
2    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 1˙116˙375.00
3    CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS FR (POITIERS CEDEX) participant 539˙188.00
4    INSERM - TRANSFERT SA FR (PARIS) participant 335˙625.00
5    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS FR (TOURS CEDEX 9) participant 203˙750.00
6    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00

Map

 Project objective

Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring major changes to contemporary healthcare provision. Therefore, the discovery and development of novel mechanism of action agents able to treat resistant infections is a key urgent need. Gepotidacin is a first in class, novel triazaacenaphthylene antibacterial that is being developed by GSK. Due to its novel mechanism of action, gepotidacin is active in vitro against most target pathogens carrying resistance determinants to established antibacterials, including fluoroquinolones. Gepotidacin has broad gram-positive activity and selective gram-negative activity and is currently under development as a treatment for infections caused by N. gonorrhoeae (urogenital gonorrhoea) and E. coli (acute uncomplicated urinary tract infections), including isolates resistant to existing classes of antimicrobials. To explore the potential of gepotidacin to treat infections caused by N. gonorrhoeae or E. coli at other body sites, the AB-DiRecT consortium will conduct a tissue distribution study in tonsil and prostate after single oral dose of gepotidacin in healthy (non-infected) subjects undergoing elective tonsillectomy or prostatectomy. Microdialysis will be used to measure gepotidacin levels in tissue following surgery and PBPK, PopPK and PKPD models will be built to understand the tissue penetration of gepotidacin to characterize exposure response and to evaluate different dose regimens. Difference between infected and healthy tissue will be explored in an animal prostatitis infection model where gepotidacin PK in plasma and tissue will be determined using microdialysis. Overall the data generated in AB-DiRecT may support the potential for clinical trials to determine the efficacy of gepotidacin for the treatment for pharyngeal N. gonorrhoeae infections and / or prostatitis caused by E. coli.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AB-DIRECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AB-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More